The US regulator reportedly will move to a single-trial default for most drug and biologic approvals, marking the agency’s ...
Chinese biotech TransThera has reported new Phase II data showing its experimental kinase inhibitor tinengotinib delivered ...
Shares of US drug developer Denali Therapeutics closed up 5.8% at $20.11 yesterday, after it announced a $275 million ...
The basal cell carcinoma market is expected to expand over the next decade as rising diagnoses, aging populations and ...
A Melbourne-based biotech company developing immune-based approaches for Alzheimer’s disease, using extracellular vesicles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback